Chemomab Therapeutics Ltd.
CMMB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $6,071 | $9,292 | $13,519 | $14,686 |
| Short-Term Investments | $8,195 | $10,492 | $26,374 | $45,975 |
| Receivables | $263 | $289 | $459 | $179 |
| Inventory | $0 | $0 | $0 | -$1,348 |
| Other Curr. Assets | $76 | $76 | $77 | $1,348 |
| Total Curr. Assets | $16,040 | $20,897 | $41,736 | $62,688 |
| Property Plant & Equip (Net) | $539 | $695 | $594 | $702 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $7 | $8 | $0 | $14 |
| Long-Term Investments | $0 | $0 | $0 | $55 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $378 | $551 | $733 | $894 |
| Total NC Assets | $924 | $1,254 | $1,327 | $1,665 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $16,964 | $22,151 | $43,063 | $64,353 |
| Liabilities | – | – | – | – |
| Payables | $666 | $516 | $1,688 | $1,336 |
| Short-Term Debt | $115 | $76 | $0 | $106 |
| Tax Payable | $0 | $0 | $351 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $759 | $747 | $0 | -$106 |
| Total Curr. Liab. | $3,218 | $4,838 | $6,749 | $2,650 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $209 | $316 | $91 | $237 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $324 | $392 | $214 | $343 |
| Total Liabilities | $3,427 | $5,154 | $6,840 | $2,887 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$102,623 | -$88,678 | -$63,819 | -$36,173 |
| AOCI | $0 | $0 | -$0 | $0 |
| Other Equity | $0 | $0 | $0 | $0 |
| Total Equity | $13,537 | $16,997 | $36,223 | $61,466 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $16,964 | $22,151 | $43,063 | $64,353 |
| Net Debt | -$5,956 | -$9,216 | -$13,519 | -$14,580 |